Selpercatinib's Impact on Early-Stage Lung Cancer

Created using ChatSlide

The study explores the rationale and design of the LIBRETTO-432 trial, focusing on RET fusions in NSCLC patients. It highlights the efficacy of adjuvant selpercatinib, showing significant improvements in two-year event-free survival rates. Safety concerns are addressed, noting a higher incidence of severe adverse events, particularly liver enzyme elevations. The findings underscore the importance of biomarker testing and suggest potential shifts in early-stage treatment practices, despite...